Open House Discount Agreements for Cabotegravir (Depot Injection Suspension)
Original notice title
Germany – Pharmaceutical products – Open house Arzneimittelrabattverträge Cabotegravir in der Darreichungsform Depot-Injektionssuspension, ATC J05AJ04
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No estimated value or guaranteed purchase volume; participation may not yield significant business.
Open-house model is not subject to procurement law; legal recourse lies with social courts, not procurement chambers.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Overview
Moderate opportunityKey Facts
- Framework procurement
- Supplies contract
- 1 lot
- Duration until May 2028
- Conclusion of non-exclusive discount agreements for Cabotegravir (ATC J05AJ04) in depot injection suspension form.
- Agreements are identical for all participants and not individually negotiable.
Show full summary
AOK Bayern is offering non-exclusive discount agreements under an open-house model for the pharmaceutical product Cabotegravir (ATC J05AJ04, depot injection suspension) to all interested pharmaceutical companies that meet eligibility criteria. The contract runs from June 2026 to May 2028, with possible termination under certain conditions. This is not a standard procurement procedure; participation is open, but no estimated value is provided.
Risks
No estimated value or guaranteed purchase volume; participation may not yield significant business.
Open-house model is not subject to procurement law; legal recourse lies with social courts, not procurement chambers.
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Eligibility
- Only pharmaceutical companies are eligible.
Administrative
- Submission of a signed self-declaration of reliability, signed contract, and filled annex on medicinal products.
- Documents must be submitted either in paper form (two original copies) or electronically with a qualified electronic signature.
Requirements may be incomplete.
Buyer
Location
München, DEU
Website
Buyer profile
Identifier
DE811695320
Activity
Health
Lots (1)
LOT-0001
Open House Discount Agreements for Cabotegravir (Depot Injection Suspension)
Single lot covering all agreements for Cabotegravir. The open-house model allows any eligible pharmaceutical company to conclude identical, non-negotiable discount agreements. The contract period is from 01.06.2026 to 31.05.2028, with rolling monthly cutoff for document submission.
Location
Duration
Category
Deadline
Award details
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Value note
Show original TED data
Original lot title
Open house Arzneimittelrabattverträge Cabotegravir in der Darreichungsform Depot-Injektionssuspension, ATC J05AJ04
Original TED description
Siehe kurze Beschreibung ACHTUNG: Die Vertragsunterlagen sind zwingend über den Kommunikationsbereich im Vergabeportal www.dtvp.de einzureichen und keinesfalls über den Angebotsbereich! BITTE BEACHTEN SIE: Die FRIST für einen Vertragsschluss zum nächsten Monatsersten endet jeweils am DRITTEN des Vormonats.
Procurement Details
- Publication date
- 14 Apr 2026
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 257297-2026
Documents (2)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Denmark – Pharmaceutical products – Amgros 2027 1.1170.a
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No estimated value or guaranteed purchase volume; participation may not yield significant business.
Open-house model is not subject to procurement law; legal recourse lies with social courts, not procurement chambers.
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications